NASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis $345.63 -4.38 (-1.25%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$345.33▼$351.6450-Day Range$311.04▼$363.5552-Week Range$208.62▼$366.08Volume275,774 shsAverage Volume492,118 shsMarket Capitalization$15.38 billionP/E Ratio16.34Dividend YieldN/APrice Target$350.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get United Therapeutics alerts: Email Address United Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.62 Rating ScoreUpside/Downside1.4% Upside$350.36 Price TargetShort InterestBearish9.47% of Float Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment0.87Based on 11 Articles This WeekInsider TradingSelling Shares$39.57 M Sold Last QuarterProj. Earnings Growth12.31%From $24.86 to $27.92 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.16 out of 5 starsMedical Sector142nd out of 910 stocksPharmaceutical Preparations Industry52nd out of 426 stocks 2.3 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 9 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageUnited Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about United Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.47% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in United Therapeutics has recently increased by 0.49%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 2.7 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for United Therapeutics this week, compared to 8 articles on an average week.Search InterestOnly 6 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,569,809.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 12.31% in the coming year, from $24.86 to $27.92 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 16.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.71.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 16.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.06.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 1.28. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about United Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About United Therapeutics Stock (NASDAQ:UTHR)United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More UTHR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UTHR Stock News HeadlinesSeptember 5 at 6:37 AM | insidertrades.comJames Edgemond Sells 7,785 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockAugust 31, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $93,722.29 in StockSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 22, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of StockAugust 9, 2024 | insidertrades.comMichael Benkowitz Sells 25,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockAugust 8, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 SharesSeptember 5 at 7:53 AM | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond Sells 7,785 SharesSeptember 2, 2024 | americanbankingnews.comAnalysts Set Expectations for United Therapeutics Co.'s Q2 2025 Earnings (NASDAQ:UTHR)September 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 30, 2024 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Sets New 12-Month High on Analyst UpgradeAugust 30, 2024 | americanbankingnews.comAnalysts Set United Therapeutics Co. (NASDAQ:UTHR) Target Price at $334.45August 29, 2024 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Price Target Increased to $575.00 by Analysts at OppenheimerAugust 28, 2024 | seekingalpha.comLiquidia requests preliminary injunction against FDA for Tyvaso 3-year exclusivityAugust 28, 2024 | finance.yahoo.comUnited Therapeutics Corporation's (NASDAQ:UTHR) Stock's On An Uptrend: Are Strong Financials Guiding The Market?August 28, 2024 | americanbankingnews.comLeerink Partnrs Equities Analysts Boost Earnings Estimates for United Therapeutics Co. (NASDAQ:UTHR)August 28, 2024 | americanbankingnews.comEquities Analysts Set Expectations for United Therapeutics Co.'s Q1 2025 Earnings (NASDAQ:UTHR)August 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for United Therapeutics on Strengthened Tyvaso Franchise PositionAugust 19, 2024 | seekingalpha.comUnited Therapeutics: Economics Support Compounding AbilitySee More Headlines Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today9/07/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,168Year Founded1996Price Target and Rating Average Stock Price Target$350.36 High Stock Price Target$575.00 Low Stock Price Target$240.00 Potential Upside/Downside+1.4%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$21.15 Trailing P/E Ratio16.34 Forward P/E Ratio13.90 P/E Growth1.28Net Income$984.80 million Net Margins40.87% Pretax Margin53.54% Return on Equity18.82% Return on Assets15.61% Debt Debt-to-Equity Ratio0.02 Current Ratio4.35 Quick Ratio4.18 Sales & Book Value Annual Sales$2.33 billion Price / Sales6.61 Cash Flow$21.60 per share Price / Cash Flow16.00 Book Value$128.05 per share Price / Book2.70Miscellaneous Outstanding Shares44,490,000Free Float38,812,000Market Cap$15.38 billion OptionableOptionable Beta0.57 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Martine A. Rothblatt J.D. (Age 69)M.B.A., Ph.D., Founder, Chairman & CEO Comp: $5.32MMr. Michael I. Benkowitz (Age 52)President & COO Comp: $2.83MMr. James C. Edgemond (Age 56)CFO & Treasurer Comp: $2.01MMr. Paul A. Mahon J.D. (Age 60)Executive VP, General Counsel & Corporate Secretary Comp: $2.31MMr. Dewey Steadman C.F.A.Head of Investor RelationsMs. Holly HobsonAssociate Vice President of Human ResourcesKevin T. GraySenior Vice President of Strategic Operations & LogisticsMr. Patrick Poisson (Age 56)Executive VP of Technical Operations Dr. Leigh PetersonExecutive Vice President of Product Development & XenotransplantationMr. Gil GoldenSenior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsTeva Pharmaceutical IndustriesNYSE:TEVAReata PharmaceuticalsNASDAQ:RETABridgeBio PharmaNASDAQ:BBIOBlueprint MedicinesNASDAQ:BPMCPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 10,896 shares on 9/5/2024Ownership: 0.025%James EdgemondSold 7,785 sharesTotal: $2.82 M ($362.37/share)Martine A RothblattSold 269 sharesTotal: $93,722.29 ($348.41/share)Cetera Investment AdvisersBought 493 shares on 8/22/2024Ownership: 0.014%Truist Financial CorpSold 694 shares on 8/21/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions UTHR Stock Analysis - Frequently Asked Questions How have UTHR shares performed this year? United Therapeutics' stock was trading at $219.89 at the beginning of 2024. Since then, UTHR shares have increased by 57.2% and is now trading at $345.63. View the best growth stocks for 2024 here. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings data on Wednesday, July, 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.33 by $0.48. The company's revenue was up 19.8% on a year-over-year basis. What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. Who are United Therapeutics' major shareholders? Top institutional investors of United Therapeutics include Renaissance Technologies LLC (4.89%), LSV Asset Management (2.18%), AQR Capital Management LLC (1.62%) and Dimensional Fund Advisors LP (1.32%). Insiders that own company stock include Paul A Mahon, Louis W Sullivan, Judy D Olian, Nilda Mesa, Christopher Causey, James Edgemond, Michael Benkowitz, Raymond Dwek, Martine A Rothblatt and Christopher Patusky. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE) and Johnson & Johnson (JNJ). This page (NASDAQ:UTHR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
